Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 22;13(5):e0197826.
doi: 10.1371/journal.pone.0197826. eCollection 2018.

Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules

John Edelsberg  1 , Derek Weycker  1 , Mark Atwood  1 , Geoffrey Hamilton-Fairley  2 , James R Jett  3
Affiliations

Cost-effectiveness of an autoantibody test (EarlyCDT-Lung) as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules

John Edelsberg et al. PLoS One. .

Abstract

Objective: Patients who have incidentally detected pulmonary nodules and an estimated intermediate risk (5-60%) of lung cancer frequently are followed via computed tomography (CT) surveillance to detect nodule growth, despite guidelines for a more aggressive diagnostic strategy. We examined the cost-effectiveness of an autoantibody test (AABT)-Early Cancer Detection Test-Lung (EarlyCDT-LungTM)-as an aid to early diagnosis of lung cancer among such patients.

Methods: We developed a decision-analytic model to evaluate use of the AABT versus CT surveillance alone. In the model, patients with a positive AABT-because they are at substantially enhanced risk of lung cancer-are assumed to go directly to biopsy, resulting in diagnosis of lung cancer in earlier stages than under current guidelines (a beneficial stage shift). Patients with a negative AABT, and those scheduled for CT surveillance alone, are assumed to have periodic CT screenings to detect rapid growth and thus to have their lung cancers diagnosed-on average-at more advanced stages.

Results: Among 1,000 patients who have incidentally detected nodules 8-30 mm, have an intermediate-risk of lung cancer, and are evaluated by CT surveillance alone, 95 (9.5%) are assumed to have lung cancer (local, 73.6%; regional, 22.0%; distant, 4.4%). With use of the AABT set at a sensitivity/specificity of 41%/93% (stage shift = 10.8%), although expected costs would be higher by $949,442 ($949 per person), life years would be higher by 53 (0.05 per person), resulting in a cost per life-year gained of $18,029 and a cost per quality-adjusted life year (QALY) gained of $24,330. With use of the AABT set at a sensitivity/specificity of 28%/98% (stage shift = 7.4%), corresponding cost-effectiveness ratios would be $18,454 and $24,833.

Conclusions: Under our base-case assumptions, and reasonable variations thereof, using AABT as an aid in the early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules who are estimated to be at intermediate risk of lung cancer and are scheduled for CT surveillance alone is likely to be a cost-effective use of healthcare resources.

PubMed Disclaimer

Conflict of interest statement

Mark Atwood, John Edelsberg, and Derek Weycker are employees of Policy Analysis Inc. (PAI), which received financial support from Oncimmune Inc. for this study. Geoffrey Hamilton-Fairley and James R. Jett are employed by, and own stock in, Oncimmune Inc. These affiliations do not alter our adherence to PLOS ONE policies on sharing data and materials (as detailed online in the guide for authors http://journals.plos.org/plosone/s/competing-interests).

References

    1. Gould MK, Tang T, Liu IA, Zheng C, Danforth KN, Kosco AE, et al. Recent trends in the identification of incidental pulmonary nodules. Am J Respir Crit Care Med 2015;192(10): 1208–14. doi: 10.1164/rccm.201505-0990OC - DOI - PubMed
    1. MacMahon H, Naidich DP, Goo JM. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1): 228–43. doi: 10.1148/radiol.2017161659 - DOI - PubMed
    1. Gould MK, Donington J, Lynch WR. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl): e93S–e120S. doi: 10.1378/chest.12-2351 - DOI - PMC - PubMed
    1. Iaccarino JM, Wiener RS. Pulmonary nodule guidelines: what physicians do when evidence-based guidelines lack high-quality evidence. Chest 2017;152(2): 232–34. doi: 10.1016/j.chest.2017.03.009 - DOI - PubMed
    1. Tanner NT, Porter A, Gould MK, Li XJ, Vachani A, Silvestri GA. Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation. Chest 2017;152(2): 263–70. doi: 10.1016/j.chest.2017.01.018 - DOI - PMC - PubMed

Publication types